levetiracetam stada mixtúra, lausn 100 mg/ml
stada arzneimittel ag - levetiracetamum inn - mixtúra, lausn - 100 mg/ml
tysabri
biogen netherlands b.v. - natalízúmab - margvísleg sclerosis - valdar ónæmisbælandi lyf - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
topimax filmuhúðuð tafla 100 mg
janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 100 mg
topimax filmuhúðuð tafla 200 mg
janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 200 mg
topimax filmuhúðuð tafla 25 mg
janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 25 mg
topimax filmuhúðuð tafla 50 mg
janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 50 mg
topimax hart hylki 15 mg
janssen-cilag ab - topiramatum inn - hart hylki - 15 mg
topiramat actavis filmuhúðuð tafla 100 mg
actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 100 mg
topiramat actavis filmuhúðuð tafla 25 mg
actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 25 mg
topiramat actavis filmuhúðuð tafla 50 mg
actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 50 mg